8th June 2025, During the 66th meeting of the Drugs Consultative Committee (DCC) held at CDSCO, New Delhi, a significant regulatory concern regarding the unauthorized issuance of manufacturing licenses for new drugs by certain State Licensing Authorities (SLAs) was deliberated. â ︅
Recent Post
- CDSCO Notifies Final Guidance Document on Medical Device Software (MDSW)
- When a “+” Sign Isn’t Just a Plus
- DCC intends to tighten control on manufacturing and supply of printed packaging materials used for drugs
- High-Alcohol Oral Formulations Move Into Schedule H1
- DCC Recommends Comprehensive Regulatory Mechanism to Curb Unapproved Drugs and FDCs
